Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Halozyme Therapeutics Inc

+ Add to Watchlist

HALO:US

14.5900 USD 0.4400 3.11%

As of 17:20:00 ET on 01/29/2015.

Snapshot for Halozyme Therapeutics Inc (HALO)

Open: 14.2000 Day's Range: 13.8328 - 14.6400 Volume: 1,065,304
Previous Close: 14.1500 52wk Range: 6.8800 - 16.8000 1-Yr Rtn: -8.35%

Stock Chart for HALO

No chart data available.
  • HALO:US 14.5800
  • 1D
  • 1M
  • 1Y
14.1500
Interactive HALO Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for HALO

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.7000
Est. EPS (USD) (12/2014) -0.5950
Est. PEG Ratio -
Market Cap (M USD) 1,828.77
Shares Outstanding (M) 125.39
30 Day Average Volume 2,564,830
Price/Book (mrq) 45.8617
Price/Sale (ttm) 30.5843
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 02/27/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for HALO

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical company developing products for the diabetes, cancer, dermatology and drug delivery markets. The Company's platform technology is based on recombinant human hyaluronidase plus additional enzymes. Halozyme applies its technology to its proprietary programs and to partnerships with pharmaceutical companies.

Helen I TorleyPresident/CEODavid A RamsayChief Financial Officer
Athena CountouriotisChief Medical OfficerH Michael Shepard "Mike"VP/Chief Scientific Officer
More Company Profile & Key Executives for HALO

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
  • HALO News

  • Industry News

No stories found
No stories found
Advertisement
Sponsored Links
Advertisements
sec ||= nil